Nagahashi, Masayuki http://orcid.org/0000-0002-9308-448X
Ling, YiWei
Toshikawa, Chie
Hayashida, Tetsu
Kitagawa, Yuko
Futamura, Manabu
Kuwayama, Takashi
Nakamura, Seigo
Yamauchi, Hideko
Yamauchi, Teruo
Kaneko, Koji
Kanbayashi, Chizuko
Sato, Nobuaki
Tsuchida, Junko
Moro, Kazuki
Nakajima, Masato
Shimada, Yoshifumi
Ichikawa, Hiroshi
Lyle, Stephen
Miyoshi, Yasuo
Takabe, Kazuaki
Okuda, Shujiro
Wakai, Toshifumi
Funding for this research was provided by:
Japan Society for the Promotion of Science (22H03140, 21K19522)
Research funding from Denka
Article History
Received: 27 October 2022
Accepted: 5 March 2023
First Online: 17 March 2023
Declarations
:
: M Nagahashi received honoraria from Chugai, AstraZeneca, Eli Lilly, Pfizer, Novartis, Taiho, Daiichi Sankyo, Esai, Kyowa-Kirin, and Denka. T Hayashida received research funding and honoraria from Eisai, Chugai, Eli Lilly, Pfizer, Kyowa-Kirin, Daiichi-Sankyo, Fixstars and Taiho. Y Kitagawa received grants and personal fees from ASAHI KASEI PHARMA CORPORATION, grants, personal fees and other from ONO PHARMACEUTICAL CO., LTD., grants and personal fees from Otsuka Pharmaceutical Factory, Inc., grants and personal fees from Nippon Covidien Inc., grants, personal fees and other from TAIHO PHARMACEUTICAL CO., LTD, grants, personal fees and other from CHUGAI PHARMACEUTICAL CO., LTD., grants and personal fees from KAKEN PHARMACEUTICAL CO.,LTD., personal fees from AstraZeneca K.K., personal fees from Ethicon Inc., personal fees from Olympus Corporation, personal fees from SHIONOGI & CO., LTD., personal fees and other from Bristol-Myers Squibb K.K., personal fees from MSD K.K., personal fees from Smith & Nephew KK, personal fees from ASKA Pharmaceutical Co., Ltd., personal fees from MIYARISAN PHARMACEUTICAL CO. LTD., personal fees from Toray Industries, Inc., personal fees from DAIICHI SANKYO COMPANY, LIMITED, personal fees from Chugai Foundation for Innovative Drug Discovery Science, personal fees from Nippon Kayaku Co., Ltd., grants from Yakult Honsha Co. Ltd., grants from Otsuka Pharmaceutical Co., Ltd., grants from TSUMURA & CO., grants from Sumitomo Pharma Co., Ltd., grants from EA Pharma Co., Ltd., grants from Eisai Co., Ltd., grants from Kyowa Kirin Co.,Ltd., grants from MEDICON INC., grants from Takeda Pharmaceutical Co., Ltd., grants from TEIJIN PHARMA LIMITED., outside the submitted work. H Yamauchi received research funding from AstraZeneca, and EIKEN Kagaku. N Sato received honorarium from Chugai Pharmaceutical, Kyowa Kirin Co. Ltd., Taiho Pharmaceutical, Eli Lilly, Nippon Kayaku Co., Daiichi Sankyo, and Celltrion Healthcare Japan. S Lyle is a paid consultant for KEW Inc. Y Miyoshi received research funding and honoraria from Esai, Chugai, AstraZeneca, Eli Lilly, Pfizer, MSD, Kyowa-Kirin, Daiichi-Sankyo, and Taiho. T Wakai, and S Okuda received research funding from Denka.